ConductScience.org, home

Paper21453545

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.

Takahashi S. J Hematol Oncol, 2011. Cited by 191 papers, by iCite.

Cite this record

ConductScience Library. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Papers, record 21453545. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21453545

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
PubMed
Journal
J Hematol Oncol
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
191
iCite
Relative citation ratio, by iCite
4.43
iCite
Revised in PubMed
2021-10-20
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Takahashi SShinichiro

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Gene Expression Regulation, LeukemicMajor topic
Leukemia, Myeloid, AcuteMajor topic
fms-Like Tyrosine Kinase 3Major topic
Animals
Humans
Mutation
Signal Transduction
Transcription Factors

Source PubMed

Download CSV of topics

References114

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112951584The role of FLT3 in haematopoietic malignancies.Nat Rev Cancer2003https://conductscience.org/library/papers/12951584PubMed
211290608Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.Blood2001https://conductscience.org/library/papers/11290608PubMed
319448675RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.Oncogene2009https://conductscience.org/library/papers/19448675PubMed
412670652Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.Bioorg Med Chem2003https://conductscience.org/library/papers/12670652PubMed
510573574Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia.Med Pediatr Oncol1999https://conductscience.org/library/papers/10573574PubMed
615498859Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.Blood2005https://conductscience.org/library/papers/15498859PubMed
715718420FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.Blood2005https://conductscience.org/library/papers/15718420PubMed
819309322Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.Eur J Haematol2009https://conductscience.org/library/papers/19309322PubMed
910502596Acute myeloid leukemia.N Engl J Med1999https://conductscience.org/library/papers/10502596PubMed
1012663439Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.Blood2003https://conductscience.org/library/papers/12663439PubMed
1120809224Targeted signal transduction therapies in myeloid malignancies.Curr Oncol Rep2010https://conductscience.org/library/papers/20809224PubMed
1220096459Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review.Leuk Res2010https://conductscience.org/library/papers/20096459PubMed
1315126317In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.Blood2004https://conductscience.org/library/papers/15126317PubMed
1417655729FLT3 inhibition in acute myeloid leukaemia.Br J Haematol2007https://conductscience.org/library/papers/17655729PubMed
157630197Expression of the flt3 receptor and its ligand on hematopoietic cells.Leukemia1995https://conductscience.org/library/papers/7630197PubMed
169454740c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities.Blood1998https://conductscience.org/library/papers/9454740PubMed
177692230Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.Mol Cell Biol1993https://conductscience.org/library/papers/7692230PubMed
1812357354Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.Leukemia2002https://conductscience.org/library/papers/12357354PubMed
1912969963FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.Blood2004https://conductscience.org/library/papers/12969963PubMed
2014630076FLT3 mutations are associated with other molecular lesions in AML.Leuk Res2004https://conductscience.org/library/papers/14630076PubMed

See all 114 referencesDownload CSV of references

Cited by138

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 191 citations.

PMIDTitleJournalYearIn PapersSource
42696088The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia.Mol Biomed2026https://conductscience.org/library/papers/42696088PubMed
42434847QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.Future Oncol2026https://conductscience.org/library/papers/42434847PubMed
42346642Hormone-Driven Growth Signaling as a Therapeutic Target in Acute Myeloid Leukemia: Implications for Drug-Resistant Disease.J Pers Med2026https://conductscience.org/library/papers/42346642PubMed
42323414SGI-7079 as a novel type I FLT3 inhibitor overcomes resistance to gilteritinib and quizartinib mediated by ITD and TKD mutations in acute myeloid leukemia.NPJ Precis Oncol2026https://conductscience.org/library/papers/42323414PubMed
42198431Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42198431PubMed
41916299Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss.Cell Rep Methods2026https://conductscience.org/library/papers/41916299PubMed
41899095Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.J Clin Med2026https://conductscience.org/library/papers/41899095PubMed
41590345Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies.Curr Oncol2026https://conductscience.org/library/papers/41590345PubMed
41463291Mitochondrial Dysfunction in Apoptosis-Resistant Acute Myeloid Leukemia Cells During a Sterile Inflammatory Response.Biomolecules2025https://conductscience.org/library/papers/41463291PubMed
41372872New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein.BMC Cancer2025https://conductscience.org/library/papers/41372872PubMed
41287669Current Therapeutic Strategies for FLT3-Mutated Acute Myeloid Leukemia: A Narrative Review.Cureus2025https://conductscience.org/library/papers/41287669PubMed
41228209FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.Cancers (Basel)2025https://conductscience.org/library/papers/41228209PubMed
41215958Understanding the characteristic behaviour of the wild-type and mutant structure of FLT3 protein by computational methods.Comput Struct Biotechnol J2025https://conductscience.org/library/papers/41215958PubMed
41095756A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts.Diagnostics (Basel)2025https://conductscience.org/library/papers/41095756PubMed
41090755Counter-Therapeutic Strategies for Resistance of FLT3 Inhibitors in Acute Myeloid Leukemia.Cells2025https://conductscience.org/library/papers/41090755PubMed
40748523Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy.Curr Oncol Rep2025https://conductscience.org/library/papers/40748523PubMed
40464185Recent Advances in FLT3-Based Dual Inhibitors: A Promising Strategy for the Treatment of Acute Myeloid Leukemia.Curr Med Chem2026https://conductscience.org/library/papers/40464185PubMed
40061103Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature.Eur Heart J Case Rep2025https://conductscience.org/library/papers/40061103PubMed
39963240Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation.Front Pharmacol2025https://conductscience.org/library/papers/39963240PubMed
39863894Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers.J Ovarian Res2025https://conductscience.org/library/papers/39863894PubMed

See all 138 cited byDownload CSV of cited by

Genes39

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BCL2L1110018PubTator's text mininghttps://conductscience.org/library/genes/10018NCBI Gene
CBFB865PubTator's text mininghttps://conductscience.org/library/genes/865NCBI Gene
CCNA2890PubTator's text mininghttps://conductscience.org/library/genes/890NCBI Gene
CCND1595PubTator's text mininghttps://conductscience.org/library/genes/595NCBI Gene
CDKN1A1026PubTator's text mininghttps://conductscience.org/library/genes/1026NCBI Gene
CDKN1B1027PubTator's text mininghttps://conductscience.org/library/genes/1027NCBI Gene
CEBPA1050PubTator's text mininghttps://conductscience.org/library/genes/1050NCBI Gene
DNMT3A1788PubTator's text mininghttps://conductscience.org/library/genes/1788NCBI Gene
FLT32322PubTator's text mininghttps://conductscience.org/library/genes/2322NCBI Gene
FLT3LG2323PubTator's text mininghttps://conductscience.org/library/genes/2323NCBI Gene
FOXO32309PubTator's text mininghttps://conductscience.org/library/genes/2309NCBI Gene
GRB22885PubTator's text mininghttps://conductscience.org/library/genes/2885NCBI Gene
HDAC99734PubTator's text mininghttps://conductscience.org/library/genes/9734NCBI Gene
HSP90AA13320PubTator's text mininghttps://conductscience.org/library/genes/3320NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
KMT2A4297PubTator's text mininghttps://conductscience.org/library/genes/4297NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MTG192170PubTator's text mininghttps://conductscience.org/library/genes/92170NCBI Gene

See all 39 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21453545

GET https://conductscience.org/api/papers/v1/21453545/references?page=2